In many clinical trials, targeting programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), has yielded favorable clinical efficacy in BC patients (3). The gene discussed is CTLA4; the disease is breast cancer.